1.
American Heart Association. 1998 Heart and stroke Statistical
Update. Dallas TX: American Heart Association; 1997
2.
Ho
KKL, Pinsky JL, Kannel WB, Levy D.
The epidemiology of Heart failure: The Famingham st. J. Am Coll
Cardiol 1993; 22(supplA): 6A-13A.
3.
Massie
BM, Shah NB.
Evolving trends in the epidemiologic factors of heart failure:
rationale for preventive stretegies and comprehensive disease management.
// Am Heart J 1997; 133:703-712.
4.
The
Digitalis Investigation Group.
The effect of digoxin onmortality and morbidity in patients with
heart failure.
//
N. Engl. Med
1997; 336, 525-533.
5.
Беленков
Ю.Н., Мареев В.Ю.
Принципы
рационального
лечения
сердечной
недостаточностию
// М:Медиа
медика 2000: 266
6.
Packer
M, Cohn JN.
Consensus Recommendations for the Management of Chronic Heart
Failure. // The American Journal of Cardiology vol 83(2A), 1999(Am J
Cardiol)
7.
Remme
WS, Swedberg K.
Guidelines on the diagnosis and management of chronic heart
failure. // Eur Heart J, 2001; 22: 1527-1560.
8.
Skarda
I., Dzerve V., Klincare D., Vitols A., Kalnins U., Dinne I., Kalvins I.
The effectiveness of a new cardioprotective agent Miidronate in the
treatment of condestive heart failure in comparison to digitalis treatment
//
15th Nordic congress of Cardiology, Abstracts, Malmo, June7-9,
1995, p.1888.
9.
Skarda
I., Dzerve, V., Klinkare, D., Vitols, A., Kalnins, U., Dinne, I., Kalvins,
I.
Influenca of long-term Mildronate treatment on quality of life and
haemodinamic parametere of congestive heart failure patients // J. Heart
Failure, 1997. V,4(1): Abstracts, 5th World Congress of Heart
Failure, Washington, D.C, USA, May 11-14, 1997, p. 53.
10.
Skarda, I., Dzerve, V., Klinkare, D., Vitols, A., Kalnins, U., Dinne, I.,
Kalvins, I.
The comparison of acute and chronic dose-dependent effects of a new
drug-Mildronate in the treatment of chronic heart failure // 2nd
International Meeteing of the Working Group on Heart Failure. Abstracts,
Cologne, Germany, May, 24-27, 1997, p. 83.
|